{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:10:19Z","timestamp":1790827819798,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1118,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Experimental Cancer Medicine Centre"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Health"},{"DOI":"10.13039\/501100000589","name":"Chief Scientist's Office","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1093\/annonc\/mdw427","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T20:27:52Z","timestamp":1476304072000},"page":"2268-2274","source":"Crossref","is-referenced-by-count":144,"title":["A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors"],"prefix":"10.1016","volume":"27","author":[{"given":"J.C.","family":"Soria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.K.","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Blagden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lemech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Peddareddigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nebot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw427_bb0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nature Rev Cancer"},{"key":"10.1093\/annonc\/mdw427_bb0015","first-page":"1701","article-title":"Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr925","volume":"1696","author":"Thapa","year":"2014","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1093\/annonc\/mdw427_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-008-9165-4","article-title":"Signal transduction by focal adhesion kinase in cancer","volume":"28","author":"Zhao","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1093\/annonc\/mdw427_bb0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1647","article-title":"The role of focal adhesion kinase in cancer: a new therapeutic opportunity","volume":"5","author":"McLean","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw427_bb0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.prp.2009.07.002","article-title":"Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues","volume":"205","author":"Ozkal","year":"2009","journal-title":"Path Res Prac"},{"key":"10.1093\/annonc\/mdw427_bb0035","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-03-3005","article-title":"Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis","volume":"64","author":"Recher","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw427_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.trsl.2010.05.001","article-title":"Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival","volume":"156","author":"Ding","year":"2010","journal-title":"Trans Res"},{"key":"10.1093\/annonc\/mdw427_bb0045","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0002-9440(10)63370-6","article-title":"Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion","volume":"165","author":"Sood","year":"2004","journal-title":"Am J Path"},{"key":"10.1093\/annonc\/mdw427_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0959-8049(12)72185-8","article-title":"The focal adhesion kinase inhibitor GSK2256098: a potent and selective inhibitor for the treatment of cancer","volume":"48","author":"Auger","year":"2012","journal-title":"Eur J Cancer"},{"issue":"Suppl. 8","key":"10.1093\/annonc\/mdw427_bb0055","article-title":"Pharmacological inhibition of focal adhesion kinase (FAK) in glioblastoma cell lines: implications for rational drug combination strategies","volume":"72","author":"Chen","year":"2012","journal-title":"Cancer Res"},{"issue":"8 Suppl.","key":"10.1093\/annonc\/mdw427_bb0060","article-title":"Enhancing anti-angiogenic therapy by blocking focal adhesion kinase","volume":"71","author":"Bottsford-Miller","year":"2011","journal-title":"Cancer Res"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdw427_bb0065","first-page":"173","article-title":"Anti-tumour activity of the focal adhesion kinase inhibitor GSK2256098C in ovarian cancer","volume":"48","author":"Doughty","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw427_bb0070","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw427_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1093\/annonc\/mdw427_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw427_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/annonc\/mdl419","article-title":"High detection rate of circulating tumor cells in blood of subjects with prostate cancer using telomerase activity","volume":"18","author":"Fizazi","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdw427_bb0090","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1158\/1078-0432.CCR-08-2363","article-title":"High levels of circulating VEGFR2+ bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies","volume":"15","author":"Taylor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw427_bb0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jim.2008.07.006","article-title":"Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay","volume":"337","author":"Jacques","year":"2008","journal-title":"J Immunol Method"},{"key":"10.1093\/annonc\/mdw427_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2593","article-title":"A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors","volume":"33","author":"Arkenau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw427_bb0105","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mdw427_bb0110","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw427_bb0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Science Trans Med"},{"key":"10.1093\/annonc\/mdw427_bb0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw427_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdw427_bb0130","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdw427_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7500","article-title":"Bevacizumab 15 mg\/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial","volume":"33","author":"Zalcman","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/12\/2268\/8623088\/mdw427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:01:40Z","timestamp":1624683700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0923753419365500"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw427","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}